NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study
TL;DR
NanoViricides Inc.'s NV-387 offers a groundbreaking advantage by potentially becoming the first drug to treat Measles, with a 130% increase in survival rates in preclinical trials.
NV-387 works by mimicking human cell features to bind and neutralize viruses, demonstrating dose-dependent efficacy and no toxicity in a lethal respiratory infection model.
With global Measles cases rising and vaccine coverage declining, NV-387 represents a critical step towards improving global health and saving lives.
Discover how NanoViricides Inc.'s innovative NV-387 could revolutionize antiviral therapy by targeting over 90% of human pathogens with its unique nanomedicine approach.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of broad-spectrum antiviral therapies, has recently announced encouraging results from a humanized animal study for its lead drug candidate, NV-387, targeting Measles. The study demonstrated a remarkable 130% increase in survival rates among humanized mice infected with a lethal dose of the virus, extending survival from 7.4 to 17 days without any observed toxicity. This breakthrough underscores the potential of NV-387 as a pioneering therapeutic solution in the fight against Measles, a disease that has seen a resurgence globally due to declining vaccine coverage.
The innovative approach of NV-387 involves mimicking human cell features to effectively bind and neutralize viruses, offering a broad-spectrum solution capable of targeting over 90% of human pathogens. With Measles cases on the rise worldwide, the development of NV-387 comes at a critical time, addressing the urgent need for effective treatment options beyond vaccination. Anil R. Diwan, PhD, highlighted the significance of these findings, stating, "NV-387 is on its way to become the very first drug to treat Measles," marking a potential turning point in antiviral therapy.
NanoViricides is now focused on advancing NV-387 into Phase II human clinical trials, with the aim of developing it as a treatment for a range of respiratory viral infections, including RSV, COVID-19, and influenza, in addition to Measles. The company's progress represents a significant step forward in the field of nanomedicine and antiviral research, offering hope for the development of effective treatments against some of the most challenging viral infections facing the global population today.
Curated from InvestorBrandNetwork (IBN)
